Skip to main content
Clinical Trials/ACTRN12620000263998
ACTRN12620000263998
Completed
未知

Distinguishing Gastroesophageal Reflux Disease and Eosinophilic Esophagitis in Adults: the Role Esopahegal Mucosal Immunoglobulin IG4

GI and Pancreatic Researchs Group0 sites60 target enrollmentFebruary 27, 2020

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
GI and Pancreatic Researchs Group
Enrollment
60
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 27, 2020
End Date
December 31, 2019
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
GI and Pancreatic Researchs Group

Eligibility Criteria

Inclusion Criteria

  • \-18\-80 years of age
  • \-typical symptoms of GERD responsive to PPI therapy
  • \-evidence of oesophagitis on endoscopy with supportive oesophageal biopsy specimens \-\-eosinophil count \<10/hpf
  • \-18\-80 years of age, symptoms of oesophageal dysfunction with 'greater than or equal to' 15 eosinophils/hpf
  • \-exclusion of other causes of eosinophilia

Exclusion Criteria

  • Exclusion criteria were history of severe respiratory, cardiovascular, hepatic, haematological and/or renal disease, chronic alcohol abuse, medications that may influence gastrointestinal function and previous gastrointestinal surgery.

Outcomes

Primary Outcomes

Not specified

Similar Trials